Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 4

Arterial Stiffness and Pharmacological Interventions – The TRanscend Arterial stiffNess Substudy (TRANS study)

Authors Jirar Topouchian, Ramzi El Feghali, Bruno Pannier, Shuyu Wang, Feng Zhao, Karel Smetana, Koon Teo, Roland Asmar

Published 15 September 2007 Volume 2007:3(4) Pages 381—388

Jirar Topouchian1, Ramzi El Feghali1, Bruno Pannier1, Shuyu Wang2, Feng Zhao3, Karel Smetana4, Koon Teo3, Roland Asmar1

1The CardioVascular Institute, Paris, France; 2Beijing Clinical Trial and Research Center, Beijing, China; 3Population Health Research Institute, Hamilton, Canada; 4Vojenska nemocnice Plzen, Pizen, Czech Republic

Abstract: The degree of arterial stiffness is correlated with the risk of cardiovascular diseases and it is a powerful predictor for morbidity and mortality. Studies have shown that arterial stiffness reduction is associated with an improvement in survival. Reduction of arterial stiffness by pharmacological drugs varies according to the drugs and doses used and duration of treatment. This effect on the arteries differs among the various classes of drugs and among individual drugs in the same class. Quantification of the stiffness and other properties of the arterial wall can be used to monitor the responses to therapy in individuals with hypertension and other cardiovascular diseases. These measures can then be used as surrogate markers for the risk of clinical events. Inhibition of the renin-angiotensin system (RAS) is associated with an important decrease in cardiovascular risk. Findings from clinical trials support the hypothesis that the protective effects of RAS inhibition are partly independent from blood pressure reduction and related to several mechanisms including vascular protective effects. The aim of the TRanscend Arterial stiffNess Substudy (TRANS) is to assess the effect of an angiotensin II receptor blocker (ARB), telmisartan, on the arterial stiffness in a subgroup of patients from the Telmisartan Randomized Assessment Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND) trial. The TRANSCEND trial is an international, multicenter, randomized double blind placebo controlled trial of telmisartan that enrolled patients at high risk for cardiovascular events. Some clinical baseline data of the TRANS substudy are reported. When completed, the results of the TRANS substudy will show whether the beneficial effects of treatment with telmisartan on cardiovascular outcome may be related to an improvement in arterial stiffness.

Keywords: arterial stiffness, cardiovascular prevention, ARBs, telmisartan, pulse wave velocity, antihypertensive

Download Article [PDF] 

Readers of this article also read:

Nanofabrication of methylglyoxal with chitosan biopolymer: a potential tool for enhancement of its anticancer effect

Pal A, Talukdar D, Roy A, Ray S, Mallick A, Mandal C, Ray M

International Journal of Nanomedicine 2015, 10:3499-3518

Published Date: 12 May 2015

Multifaceted prospects of nanocomposites for cardiovascular grafts and stents

Vellayappan MV, Balaji A, Subramanian AP, John AA, Jaganathan SK, Murugesan S, Supriyanto E, Yusof M

International Journal of Nanomedicine 2015, 10:2785-2803

Published Date: 7 April 2015

Major risk factors for the appearance of white-matter lesions on MRI in hypertensive patients with controlled blood pressure

Takami T, Yamano S, Okada S, Sakuma M, Morimoto T, Hashimoto H, Somekawa S, Saito Y

Vascular Health and Risk Management 2012, 8:169-176

Published Date: 14 March 2012

Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension

Martin Thoenes, Jan-Christian Reil, Bobby Varkey Khan, Peter Bramlage, et al.

Vascular Health and Risk Management 2009, 5:577-585

Published Date: 13 July 2009

Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature

Gaetano Zaccara, Luigi M Specchio

Neuropsychiatric Disease and Treatment 2009, 5:249-259

Published Date: 28 April 2009

A review of nateglinide in the management of patients with type 2 diabetes

Nicholas Tentolouris, Christina Voulgari, Nicholas Katsilambros

Vascular Health and Risk Management 2007, 3:797-807

Published Date: 15 January 2008

Short-term effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity

Barbara Ludolph, Wilhelm Bloch, Malte Kelm, Rainer Schulz, Petra Kleinbongard

Vascular Health and Risk Management 2007, 3:1069-1073

Published Date: 15 January 2008

Adult nontwin sib concordance rates for type 2 diabetes, hypertension and metabolic syndrome among Asian Indians: The Indian Atherosclerosis Research Study

Jayashree Shanker, Saikat Kanjilal, Veena S Rao, Ganapathy Perumal, Natesha B Khadrinarasimhiah, et al

Vascular Health and Risk Management 2007, 3:1063-1068

Published Date: 15 January 2008

Atherogenic lipid profiles and its management in patients with rheumatoid arthritis

Michael T Nurmohamed

Vascular Health and Risk Management 2007, 3:845-852

Published Date: 15 January 2008

Nebivolol in the treatment of chronic heart failure

Angie Veverka, Jennifer L Salinas

Vascular Health and Risk Management 2007, 3:647-654

Published Date: 15 November 2007